{"groups":[{"description":"Patients receive trametinib dimethyl sulfoxide 2mg PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.","id":"FG000","title":"Treatment (Trametinib)"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Ineligible"},{"reasons":[{"groupId":"FG000","numSubjects":"3"}],"type":"Never Started Treatment"},{"reasons":[{"groupId":"FG000","numSubjects":"10"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"2"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"25"}],"type":"Disease Progression"},{"reasons":[{"groupId":"FG000","numSubjects":"2"}],"type":"Other Complicating Disease"},{"reasons":[{"groupId":"FG000","numSubjects":"4"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Patient Refusal - Prefers Different Therapy"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Non-Compliance"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Still on Treatment"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"50"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"49"}],"type":"Eligible"},{"achievements":[{"groupId":"FG000","numSubjects":"46"}],"comment":"Three patients never started treatment. This is the primary analysis population.","type":"Eligible and Started Protocol Therapy"},{"achievements":[{"groupId":"FG000","numSubjects":"0"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"50"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"To be assigned to a specific MATCH subprotocol, patients needed to submit a tumor biopsy for molecular characterization and those with molecular variants addressed by treatments included in the trial entered corresponding MATCH subprotocol. For the subprotocol S1, patients had to have a qualifying NF1 actionable mutation.","recruitmentDetails":"Eighty-one patients were assigned to Subprotocol S1 after screening, all from screening cohort. Of the 81 patients, 50 patients were enrolled in arm S1 between March 2016 and July 2017."}